Clinical Trials Logo

Activated PI3K-delta Syndrome clinical trials

View clinical trials related to Activated PI3K-delta Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT03383380 Recruiting - Clinical trials for Activated PI3K-delta Syndrome

Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome

Start date: December 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this proposed research is to evaluate the efficacy and safety of the rapamycin therapy in patients with activated phosphoinositide 3-kinase δ syndrome (APDS).

NCT ID: NCT02593539 Completed - Clinical trials for Activated PI3K-delta Syndrome

Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI

Start date: July 22, 2016
Phase: Phase 2
Study type: Interventional

This is an open-label study conducted to investigate safety, pharmacokinetics and pharmacodynamics of repeat doses of inhaled nemiralisib (NEMI) in participants with activated phosphoinositide 3-kinase (PI3K) delta syndrome /p110 delta-activating mutation causing senescent T Cells, lymphadenopathy and immunodeficiency (APDS/PASLI)